Study of TS-1 as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer
Status:
Unknown status
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effectiveness and safety profile of Aiyi®(Tegafur
Gimeracil Oteracil Potassium Capsule, TS-1) as a second line therapy in Chinese female
patients with advanced metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Chinese Academy of Medical Sciences
Collaborators:
Beijing Cancer Hospital Beijing Chao Yang Hospital China-Japan Friendship Hospital Chinese PLA General Hospital Hebei Tumor Hospital Tianjin Medical University Cancer Institute and Hospital